40 Biotechnology Stocks to Sell Now

40 Biotechnology Stocks to Sell Now

The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Regeneron Pharmaceuticals, Inc.’s (REGN) rating weakens this week, dropping to a F versus last week’s D. Regeneron Pharmaceuticals, Inc. researches, develops and commercializes therapeutics to treat human disorders and conditions. For more information, get Portfolio Grader’s complete analysis of REGN stock.

This week, Agios Pharmaceuticals, Inc.’s (AGIO) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of AGIO stock.

Slipping from a C to a D rating, Spark Therapeutics, Inc. (ONCE) takes a hit this week. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of ONCE stock.

SAGE Therapeutics, Inc. (SAGE) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of SAGE stock.

Neurocrine Biosciences, Inc. (NBIX) is having a tough week. The company’s rating falls from a C to a D. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

This is a rough week for Alnylam Pharmaceuticals, Inc (ALNY). The company’s rating falls to F from the previous week’s D. Alnylam Pharmaceuticals, Inc engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALNY stock.

This week, Ophthotech Corp. (OPHT) drops from a D to a F rating. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

Alder Biopharmaceuticals, Inc. (ALDR) declines this week from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDR stock.

Juno Therapeutics, Inc. (JUNO) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of JUNO stock.

Retrophin, Inc. (RTRX) slips from a C to a D this week. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of RTRX stock.

Bellicum Pharmaceuticals Inc (BLCM) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BLCM stock.

Flexion Therapeutics, Inc. (FLXN) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

This is a rough week for Forward Pharma A/S Sponsored ADR (FWP). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of FWP stock.

This week, Voyager Therapeutics, Inc.’s (VYGR) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of VYGR stock.

Esperion Therapeutics, Inc. (ESPR) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ESPR stock.

CytomX Therapeutics, Inc. (CTMX) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CTMX stock.

Cidara Therapeutics, Inc. (CDTX) declines this week from a D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CDTX stock.

This week, MiMedx Group, Inc. (MDXG) drops from a C to a D rating. MiMedx Group, Inc. operates as a medical device company. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MDXG stock.

Recro Pharma, Inc. (REPH) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of REPH stock.

Immune Design Corp. (IMDZ) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

Inovio Pharmaceuticals, Inc.’s (INO) rating weakens this week, dropping to a D versus last week’s C. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company also gets F’s in sales growth, earnings growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of INO stock.

Slipping from a D to a F rating, NantKwest, Inc. (NK) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NK stock.

Ignyta, Inc. (RXDX) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXDX stock.

This is a rough week for Synergy Pharmaceuticals, Inc. (SGYP). The company’s rating falls to D from the previous week’s C. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Vital Therapies, Inc. (VTL) slips from a D to a F this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTL stock.

Cyclacel Pharmaceuticals, Inc. (CYCC) declines this week from a C to a D. Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CYCC stock.

This week, Adaptimmune Therapeutics PLC Sponsored ADR’s (ADAP) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

Slipping from a D to a F rating, Caladrius Biosciences, Inc. (CLBS) takes a hit this week. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLBS stock.

Aeterna Zentaris Inc. (AEZS) earns a D this week, moving down from last week’s grade of C. Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with expertise in drug discovery, development and commercialization. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AEZS stock.

This week, aTyr Pharma, Inc. (LIFE) drops from a D to a F rating. ATyr Pharma, Inc. offers a broad range of products and services, including systems, instruments, reagents, and custom services. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LIFE stock.

Organovo Holdings, Inc.’s (ONVO) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

Onconova Therapeutics Inc. (ONTX) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONTX stock.

Lpath, Inc. (LPTN) is having a tough week. The company’s rating falls from a C to a D. Lpath, Inc. is a drug discovery company with a focus on bioactive signaling lipids as targets for treating and diagnosing human diseases. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPTN stock.

This is a rough week for Rigel Pharmaceuticals, Inc. (RIGL). The company’s rating falls to D from the previous week’s C. Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RIGL stock.

PDL BioPharma, Inc. (PDLI) gets weaker ratings this week as last week’s D drops to a F. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company also gets F’s in sales growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PDLI stock.

Nivalis Therapeutics, Inc.’s (NVLS) rating weakens this week, dropping to a F versus last week’s D. Nivalis Therapeutics, Inc. manufactures, sells, and supports equipment used in the fabrication of chips and semiconductors. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVLS stock.

Idera Pharmaceuticals, Inc. (IDRA) declines this week from a D to a F. Idera Pharmaceuticals, Inc. is engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like Receptors (TLRs) to treat infectious diseases, autoimmune and inflammatory diseases, cancer, asthma and allergies, and for use as vaccine adjuvants. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of IDRA stock.

Pluristem Therapeutics Inc. (PSTI) earns a D this week, moving down from last week’s grade of C. Pluristem Therapeutics Inc. develops Messenchymal stem cell production technology and commercializes cell therapy products. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PSTI stock.

RXi Pharmaceuticals Corporation (RXII) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXII stock.

Slipping from a D to a F rating, Novavax, Inc. (NVAX) takes a hit this week. Novavax, Inc. creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVAX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/12/40-biotechnology-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC